The following is a summary of the Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Capricor Therapeutics reported a Q1 cash balance of around $39.9 million, up from $39.5 million at the end of 2023. The company expects the cash runway to extend into the first quarter of 2025, excluding potential additional milestone payments from Nippon Shinyaku.

• Received a $10 million milestone payment from distribution partner Nippon Shinyaku.

• Raised approximately $3.5 million in gross proceeds under the at-the-market program at an average price of $5.75 per share. A majority of these funds were raised in Q2 at over $6.75 per share.

• Research and development expense was approximately $10.1 million, up by $2.9 million mainly due to increased clinical and manufacturing costs related to Phase 3 HOPE-3 clinical trial.

• General and administrative expense was approximately $1.8 million, consistent with Q1 2023.

• Q1 2024 net loss was approximately $9.8 million, an increase from a net loss of approximately $7.8 million for the same period in the previous year.

Business Progress:

• Capricor Therapeutics saw significant progress in the Duchenne Muscular Dystrophy (DMD) Program and its exosome platform technology.

• Stable enrollment progress was seen in the HOPE-3 Phase 3 pivotal trial, with top-line data expected by late 2024.

• A potential financial opportunity of $90 million, in potential milestone payments, is associated with regulatory achievements with Nippon Shinyaku.

• Capricor is planning to launch its exosome-based product to the clinic by 2024.

• The company is collaborating with Nippon Shinyaku for the commercialization of CAP-1002.

• Capricor is collaborating with the National Institutes of Allergy and Infectious Disease (NIAID) for testing vaccine candidates for potential use in preventing COVID-19.

• The company presented data on the potential treatment for arginase-1 deficiency using its exosome platform.

• The company is planning the commercial and regulatory progress of CAP-1002, including discussions about reimbursement and potential label expansion for the drug.

More details: Capricor Therapeutics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.